27828-71-3

Basic information

• Product Name: 5-Hydroxynicotinic acid
• Synonyms: 5-Hydroxypyridine-3-carboxylic acid, 3-Carboxy-5-hydroxypyridine;5-Hydroxy-pyridin-3-carboxylic acid;Nicotinic acid, 5-hydroxy-;5-hydroxy-3-pyridinecarboxylicaci;5-hydroxy-nicotinicaci;3-PYRIDINECARBOXYLIC ACID, 5-HYDROXY-;5-HYDROXYNICOTINIC ACID;5-HYDROXYPYRIDINE-3-CARBOXYLIC ACID
• CAS NO: 27828-71-3
• Molecular Formula: C₆H₅NO₃
• Molecular Weight: 139.11
• EINECS: -0
• Product Categories: Nicotine Derivatives;Pharmaceuticals;blocks;Carboxes;Pyridines;Acids and Derivatives;Heterocycles;pharmacetical;Pyridine series;Carboxylic Acids;Pyridine;Organic acids;Carboxylic Acids;Aromatics;Intermediates & Fine Chemicals
• Mol File: 27828-71-3.mol

Chemical Properties

• Melting Point: 299 °C
• Boiling Point: 519.3 °C at 760 mmHg
• Flash Point: 267.9 °C
• Appearance: /
• Density: 1.485 g/cm³
• Vapor Pressure: 1.3E-11mmHg at 25°C
• Storage Temp.: Keep Cold
• PKA: 2.08±0.10(Predicted)
• BRN: 115847
• CAS DataBase Reference: 5-Hydroxynicotinic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Hydroxynicotinic acid(27828-71-3)
• EPA Substance Registry System: 5-Hydroxynicotinic acid(27828-71-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-37/39
• WGK Germany: 3
• RTECS: QT1757500
• HazardClass: IRRITANT
• Hazardous Substances Data: 27828-71-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
5-Hydroxynicotinic acid is used as a research compound for investigating the hydroxylation mechanism of the flavoprotein 2-methyl-3-hydroxypyridine-5-carboxylic acid oxygenase (MHPCO). This application aids in understanding the metabolic pathways and potential therapeutic targets related to nicotinic acid metabolism.
Used in Platelet Metabolism Studies:
5-Hydroxynicotinic acid is used as an inhibitor in the study of platelet metabolism, specifically in the context of nicotinic acid metabolism. Its inhibitory effect on human platelets can provide insights into the regulation of platelet function and its potential implications in various diseases and conditions.
Used in Chemical Synthesis:
As a nicotinic acid analog, 5-Hydroxynicotinic acid can be used as a starting material or intermediate in the synthesis of various chemical compounds, particularly those with potential pharmaceutical or biological applications. Its unique structure allows for further modification and exploration of its properties and potential uses in different industries.

InChI:InChI=1/C6H5NO3/c8-5-1-4(6(9)10)2-7-3-5/h1-3,8H,(H,9,10)/p-1

Upstream product

• 24242-19-1 5-aminonicotinic acid 
• 36052-25-2 5-amino-nicotinic acid methyl ester 
• 20826-04-4 5-bromo-3-pyridinecarboxylic acid 

Downstream Products

• 59288-43-6 5-hydroxy-6-nitropyridine-3-carboxylic acid 
• 219817-42-2 methyl 5-(benzyloxy)nicotinate 
• 59288-38-9 ethyl 5-hydroxy-3-pyridinecarboxylate 
• 30766-22-4 methyl 5-hydroxy-3-pyridinecarboxylate 
• 1202633-59-7 HOC₅H₃NCOOSn(C₆H₅CH₂)3 
• 1202633-58-6 HOC₅H₃NCOOSn(C₆H₅)3 
• 1264263-57-1 (S)-allyl 2-(benzyloxycarbonylamino)-3-(5-hydroxy-N-methylnicotinamido)propanoate 
• 1252655-89-2 tert-butyl [(5-{[4-(2-tert-butylphenyl)piperazin-1-yl]carbonyl}pyridin-3-yl)oxy]acetate 
• 1252655-90-5 [(5-{[4-(2-tert-Butylphenyl)piperazin-1-yl]carbonyl}pyridin-3-yl)oxy]acetic acid 
• 1252658-13-1 C₂₀H₂₅N₃O₂ 
• 1400807-93-3 C₁₄H₁₄N₂O₂ 
• 1400807-94-4 C₁₄H₁₃N₅O 
• 1400807-96-6 5-(benzyloxy)pyridine-3-carbonitrile 
• 1400807-97-7 C₁₃H₁₁N₅O 

Relevant articles and documents

NEW HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS

The invention is related to compound which comprises at least one radical C=Y, Y being O or S, and an oxidable and non protonable nitrogen atom N wherein the distance (d) between the at least one carbon atom of the radical group C=Y and the nitrogen atom, when oxidized, is comprised between 0.3 and 0.8 nanometers. The invention is related to new heterocyclic compounds defined by formula G, their preparation, to pharmaceutical compositions comprising them and to their use as therapeutic agents, particularly in the treatment of neurodegenerative or Alzheimer disease.

Hydroxy- and amino-substituted piperidinecarboxylic acids as γ-aminobutyric acid agonists and uptake inhibitors

The syntheses of (3RS, 4RS)-4-hydroxypiperidine-3-carboxylic acid (4), (3RS, 5SRJ-5-hydroxypiperiden-3-carboxylic acid (20), (3RS, 4SR)-4-acetamidopiperidine-3-carboxylic acid (10), and (3RS, 5SR)-5-acetamidopiperidine-3-carboxylic acid (18), related to the specific γ-aminobutyric (GABA) uptake inhibitors (RS)-piperidine-3-carboxylic acid (nipecotic acid) and (3RS, 4SR)-4-hydroxypiperidine-3-carboxylic acid (21), are described. Furthermore, (3RS, 4SR)-3-hydroxypiperidine-4-carboxylic acid (14), related to the specific GABA agonist piperidine-4-carboxylic acid (isonipecotic acid), has been synthesized. The structures of 4, 10, 14, 18, and 20 have been established by 270-MHz 1H NMR spectroscopic analyses. The affinity of the compounds for the GABA receptors and for the neuronal (synaptosomal) GABA uptake system in vitro has been measured. Compound 14 interacts selectively with the GABA receptors but less effectively than isonipecotic acid and the cis-isomer 22. Compounds 4, 18, and 20 are inhibitors of the GABA uptake system, although much weaker than nipecotic acid and (3RS, 4SR)-4-hydroxypiperidine-3-carboxylic acid (21). Compound 10 is inactive in both test systems.